Table 1.
Participant demographics and medical characteristics
| Participant characteristics | n=26 | % |
|---|---|---|
| Age | ||
| Mean 66.7 years | ||
| Range 51–82 years | ||
| Sex | ||
| Male | 11 | 42.3 |
| Female | 15 | 57.7 |
| Occupation | ||
| Retired | 19 | 73.1 |
| Domestic duties | 3 | 11.6 |
| Disability pensioner | 2 | 7.7 |
| Manager | 1 | 3.8 |
| Sales assistant | 1 | 3.8 |
| Cultural background | ||
| Aboriginal and Torres Strait Islander | 1 | 3.8 |
| Culturally and linguistically diverse | 1 | 3.8 |
| Caucasian | 24 | 92.3 |
| Highest level of education attained | ||
| Tertiary studies | 4 | 15.4 |
| Year 11–12 | 2 | 7.7 |
| Year 9–10 | 13 | 50 |
| Year 7–8 | 7 | 27 |
| Time since COPD diagnosis | ||
| >15 years | 7 | 27 |
| 10–15 years | 3 | 11.6 |
| 6–10 years | 8 | 30.8 |
| 1–5 years | 8 | 30.8 |
| Number of self-reported comorbidities | ||
| >2 | 10 | 38.5 |
| 2 | 9 | 34.6 |
| 1 | 5 | 19.2 |
| 0 | 2 | 7.7 |
| Self-reported comorbidities | ||
| Arthritis/joint pain | 10 | 38.5 |
| Asthma | 7 | 27 |
| Hypertension | 5 | 19.2 |
| Obstructive sleep apnea | 5 | 19.2 |
| Diabetes mellitus | 5 | 19.2 |
| Osteoporosis | 4 | 15.4 |
| Cardiovascular disease | 3 | 11.6 |
| Hypercholesterolemia | 2 | 7.7 |
| Other | 17 | 65.4 |
| Self-reported medications taken for COPD | ||
| Mean 3.5 (range 1–5) | ||
| Short-acting β-agonists (SABAs) | 14 | 53.8 |
| Long-acting muscarinic antagonists (LAMAs) | 13 | 50.0 |
| Combination inhaled glucocorticoids and long-acting β-agonists (LABAs) | 11 | 42.3 |
| LABAs/LAMAs | 3 | 11.6 |
| Inhaled or oral glucocorticoids | 5 | 19.2 |